• Mutation; HGNC; HGNC:7427; MT-CYB; Simple; p.Glu271Lys (m.15557G>A); ClinVar=VCV000693906; Zygosity=Heteroplasmic; Note=In 70.3% (PubMed=16778181).
  
• Mutation; HGNC; HGNC:7455; MT-ND1; Simple; p.Gly101Ter (m.3571insC); Zygosity=Heteroplasmic; Note=In 94.3% (PubMed=16778181).
  
• Mutation; HGNC; HGNC:8607; PRKN; Simple; p.Val380Leu (c.1138G>C); ClinVar=VCV000041221; Zygosity=Homozygous; Note=Germline (PubMed=26354775).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro151Thr (c.451C>A); ClinVar=VCV000012369; Zygosity=Homozygous (PubMed=31443247).
  

PubMed=9669284; DOI=10.1089/thy.1998.8.475
Zielke A., Tezelman S., Jossart G.H., Wong M.G., Siperstein A.E., Duh Q.-Y., Clark O.H.
Establishment of a highly differentiated thyroid cancer cell line of Hurthle cell origin.
Thyroid 8:475-483(1998)

PubMed=11349830; DOI=10.1089/10507250152039055
Savagner F., Chevrollier A., Loiseau D., Morgan C., Reynier P., Clark O.H., Stepien G., Malthiery Y.
Mitochondrial activity in XTC.UC1 cells derived from thyroid oncocytoma.
Thyroid 11:327-333(2001)

PubMed=16646677; DOI=10.1089/thy.2006.16.325
Stankov K., Biondi A., D'Aurelio M., Gasparre G., Falasca A., Romeo G., Lenaz G.
Mitochondrial activities of a cell line derived from thyroid Hurthle cell tumors.
Thyroid 16:325-331(2006)

PubMed=16778181; DOI=10.1158/0008-5472.CAN-06-0171
Bonora E., Porcelli A.M., Gasparre G., Biondi A., Ghelli A., Carelli V., Baracca A., Tallini G., Martinuzzi A., Lenaz G., Rugolo M., Romeo G.
Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III.
Cancer Res. 66:6087-6096(2006)

PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)

PubMed=19087340; DOI=10.1186/1471-2407-8-371; PMCID=PMC2651892
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371.1-371.11(2008)

PubMed=26354775; DOI=10.1093/carcin/bgv122
Lee J., Ham S., Lee M.H., Kim S.J., Park J.H., Lee S.E., Chang J.Y., Joung K.H., Kim T.Y., Kim J.M., Sul H.J., Kweon G.R., Jo Y.S., Kim K.S., Shong Y.K., Gasparre G., Chung J.K., Porcelli A.M., Shong M.
Dysregulation of Parkin-mediated mitophagy in thyroid Hurthle cell tumors.
Carcinogenesis 36:1407-1418(2015)

PubMed=29066502; DOI=10.1530/ERC-17-0288
Corver W.E., Demmers J., Oosting J., Sahraeian S., Boot A., Ruano D., van Wezel T., Morreau H.
ROS-induced near-homozygous genomes in thyroid cancer.
Endocr. Relat. Cancer 25:83-97(2018)

PubMed=31443247; DOI=10.3390/cancers11081185; PMCID=PMC6721552
Aydemirli M.D., Corver W.E., Beuk R., Roepman P., Solleveld-Westerink N., van Wezel T., Kapiteijn E.H.W., Morreau H.
Targeted treatment options of recurrent radioactive iodine refractory Hurthle cell cancer.
Cancers (Basel) 11:1185.1-1185.16(2019)